Dutasteride for Androgenetic Alopecia
Verdict: Published with Warning
Across 4 PubMed studies, the evidence for Dutasteride in Androgenetic Alopecia grades Tier A — moderate evidence. Effective, but with safety or population caveats.
A 🔵 A Moderate Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.64
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published with Warning
Confidence
85%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.639
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (4)L2 · primary research & systematic reviews
Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian network meta-analysis
Finding: Dutasteride 0.5 mg increased terminal hair density by 18.37 TH/cm^2 vs placebo at 24 weeks (statistically significant); finasteride 1 mg gave 12.38 TH/cm^2 but lost significance at 24 weeks. Dutasteride ranked among the top pharmacological treatments; direct dutasteride vs finasteride contrast did not reach significance, but dutasteride showed stronger magnitude.
View on PubMed The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis
Finding: Dutasteride produced a mean hair-count increase of +28.57 hairs vs finasteride (95% CI 18.75 to 38.39, p<0.00001); sexual adverse-event rates were comparable between groups.
View on PubMed Effectiveness and Safety of Intralesional Dutasteride in Patients With Androgenic Alopecia: A Systematic Review and Meta-Analysis
Finding: Pooled improvement rate 75% (95% CI 56-88%, p<0.0001); pooled hair-density mean difference -1.37 (95% CI -16.89 to 14.15) — wide CI crossing zero, so improvement signal is driven by responder-rate proportions rather than density MD; well tolerated with minimal local AEs.
View on PubMed Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia
Finding: Target-area hair count, hair width, and investigator global appearance all improved from baseline at week 52 (open-label, no comparator); drug-related AE rate 17% (nasopharyngitis, ED, decreased libido), none caused withdrawal.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
AVODART is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: improve symptoms, reduce the risk of acute urinary retention (AUR), and reduce the risk of the need for BPH-related surgery. AVODART is not approved for the prevention of prostate cancer. source↗
L4c UK NHS
Cautious
Dutasteride. Indications and dose — Benign prostatic hyperplasia. By mouth. For adult: 500 micrograms once daily, review treatment at 3–6 months and then every 6–12 months. ... Contra-indications: Women; children. ... Cautions: Patients should be assessed for prostate cancer before treatment and at regular intervals afterwards — dutasteride reduces serum prostate specific antigen (PSA) concentr… source↗
L4d TW TFDA / 衛福部
Cautious
Dutasteride（適尿通 Avodart 0.5mg 軟膠囊）為醫師處方用藥，核可適應症為良性攝護腺肥大（BPH），仿單載明可能引起性功能障礙（性慾減退、勃起功能障礙、射精異常）及男性乳房異常變化等不良反應，部分症狀於停藥後仍可能持續。 source↗
L4e WHO
Not addressed
Finasteride and dutasteride: prostate cancer (WHO Drug Information / WHO Pharmaceuticals Newsletter signal communication) source↗
L5d Harvard Health
Neutral
Dutasteride (Avodart) is not approved in the United States to be used for hair loss but sometimes is prescribed to treat it. source↗
L5e Specialty Society (condition-mapped)
Supportive
Dutasteride is strongly recommended for the treatment of male pattern hair loss (Grade A).